Gary A. Lyons, Director of Neurocrine Biosciences NBIX, has filed 0 purchases and 11 sales on the open market. Over the past 12 months that comes to a net sale of $2.6M. The latest trade was on 05/27.

GL

GL

Gary A. Lyons

Director

Company

Neurocrine Biosciences NBIX

First filing

23/02/02

Trades

55 trades

Buys / sales

0 / 11

12-month net buying

−$2.6M

Last trade

05/27

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Travere TherapeuticsTVTX	Open-market sale10b5-1 plan	04/14	04/16	8,000 sh	$41.07	$328,560	−12.2%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/12/03	25/12/04	15,000 sh	$152.61	$2,289,150	−11.1%
Travere TherapeuticsTVTX	Open-market sale10b5-1 plan	24/10/04	24/10/04	40,000 sh2 trades	$14.73avg.	$589,056.8	−44.0%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/08/13	24/08/15	11,570 sh	$150.43	$1,740,475.1	−8.9%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/07/16	24/07/18	930 sh	$150.03	$139,527.9	−0.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/05/14	24/05/16	12,500 sh	$135.63	$1,695,375	−9.7%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/12/22	23/12/27	10,000 sh	$130.04	$1,300,400	−4.9%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/12/01	23/12/05	5,000 sh	$116.77	$583,850	−2.4%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/09/12	23/09/14	5,000 sh	$115.02	$575,100	−2.4%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/09/01	23/09/06	5,000 sh	$110.06	$550,300	−2.4%